Navigation Links
Boston Scientific Announces Results for Third Quarter Ended September 30, 2008
Date:10/21/2008

)

Restructuring-related charges, net of tax $25

Litigation-related charges:

Litigation-related charges $334

Income tax benefit (d) (68)

Litigation-related charges, net of tax $266

Divestiture-related (gains) losses:

Gain on sale of investments (c) $(15)

Loss on assets held for sale $352

(15) 352

Income tax benefit (d) (11)

Divestiture-related (gains) losses, net of tax $(26) $352

Intangible asset impairment charges:

Intangible asset impairment charges $155

Income tax benefit (d) (26)

Intangible asset impairment charges, net of tax $129

Amortization expense:

Amortization expense $131 $155

Income tax benefit (d) (35) (19)

Amortization expense, net of tax $96 $136

(a) Recorded $8 million to selling, general and administrative expenses

and $2 million to cost of products sold.

(b) Recorded $4 million to cost of products sold; $9 million to selling,

general and administrative expenses; $1 million to research and

development expenses; and $20 million to restructuring charges.

(c) Recorded to other, net.

(d) Amounts are tax effected at the Company's effective tax rate, unless

the amount is a significant unusual or infrequently occurring item in

accordance with FASB Interpretation No. 18, "Accounting for Income

Taxes in Interim Periods."

An explanation of the Company's use of these non-GAAP measures is provided at the end of this document.


'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27

Related biology technology :

1. Boston Scientific Provides Comments Reinforcing Strength of Its Balance Sheet
2. Boston Scientific Provides Update on Involuntary Selling of Its Stock by Co-Founders
3. Video: Boston Scientific Announces FDA Approval of Second-Generation TAXUS(R) Liberte(R) Drug-Eluting Stent
4. Boston Scientific Announces FDA Approval of TAXUS(R) Express2(TM) Atom(TM) Stent System, First Drug-Eluting Stent For Small Vessels
5. Boston Scientific to Participate in UBS Global Life Sciences Conference
6. Boston Scientific Announces Court Decision
7. IBC Life Sciences Kicks Off the 13th Annual Drug Discovery & Development of Innovative Therapeutics World Congress in Boston, Massachusetts
8. InNexus Biotechnology CEO and Chief Scientific Officer to Present at IBCs Annual World Congress Conference in Boston on Aug 6th
9. NorthPoint Domain and Boston Medical Center Partner to Apply Advanced Patient Engagement Instruments to Pioneering Cardiac Robotic Surgery Program
10. TechCFO Adds Gary Strickland as Partner in Boston Office
11. Boston Scientific Announces FDA Approval for PROMUS(TM) Everolimus-Eluting Coronary Stent System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... 1, 2015 Pfenex Inc. (NYSE MKT: ... development of biosimilar therapeutics including high value and ... first quarter 2015 financial results will be released ... of market. At 8:30 am Eastern Time, Pfenex management ... financial results and provide a business update. A press ...
(Date:5/1/2015)... 1, 2015 According to ... Product (Equipment, Consumables), by Type (Monoclonal, Polyclonal), by ... Research Institutes) - Analysis & Global Forecast to ... global Antibody Production Market for the forecast period ... to reach $2.572 Billion by 2019 from $1.425 ...
(Date:4/30/2015)... Cytokinetics, Incorporated (Nasdaq: CYTK) reported total research ... $4.4 million, compared to $8.0 million during the same period ... was $8.9 million, or $0.23 per basic and diluted share. ... period in 2014, of $8.7 million, or $0.27 per basic ... cash equivalents and investments totaled $117.5 million. , "During ...
(Date:4/30/2015)... & Budapest, Hungary (PRWEB) April 30, 2015 ... web-based electronic lab notebook with integrated protocols and ... providing chemistry software solutions and consulting services for ... to the development of Labguru’s newest feature: chemical ... of deep domain features for biologists, bio-chemists, and ...
Breaking Biology Technology:Pfenex To Report First Quarter 2015 Results and Provide Business Update on Thursday, May 14, 2015 2Antibody Production Market worth $2.572 Billion by 2019 2Antibody Production Market worth $2.572 Billion by 2019 3Antibody Production Market worth $2.572 Billion by 2019 4Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 2Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 3Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 4Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 5Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 6Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 7Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 8Labguru Integrates ChemAxon's Marvin JS, to Enhance Functionality for Chemists 2
... Nektar Therapeutics,(Nasdaq: NKTR ) announced today that ... NKTR-102 in platinum-resistant ovarian cancer. Regulatory approvals,have also ... additional,trials: a randomized Phase 2 study to evaluate NKTR-102 ... gene mutation, and a,Phase 2 study in metastatic breast ...
... - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ... has been granted its 31st U.S. Patent, # ... The patent includes claims to pharmaceutical compositions containing ... our proprietary position for REOLYSIN(R)," said Mary Ann ...
... Support Development of Micromet,s EpCAM-specific Antibody Therapeutics BETHESDA, ... (Nasdaq: MITI ), a biopharmaceutical company ... cancer, inflammation and autoimmune diseases today announced the ... Nature Cell Biology (1) revealing a novel ...
Cached Biology Technology:First Patient Dosed in Phase 2 Clinical Trial of NKTR-102 in Ovarian Cancer 2First Patient Dosed in Phase 2 Clinical Trial of NKTR-102 in Ovarian Cancer 3First Patient Dosed in Phase 2 Clinical Trial of NKTR-102 in Ovarian Cancer 4Oncolytics Biotech Inc. Announces Issuance of 31st U.S. Patent 2Data Published in Nature Cell Biology Reveal Novel Function of Drug Target EpCAM in Cancer Cell Signalling 2Data Published in Nature Cell Biology Reveal Novel Function of Drug Target EpCAM in Cancer Cell Signalling 3Data Published in Nature Cell Biology Reveal Novel Function of Drug Target EpCAM in Cancer Cell Signalling 4
(Date:4/2/2015)... -- Fingerprint Cards (FPC) has received an ... distributor World Peace Industrial Group (WPI), part of WPG ... major part of the shipments will take place during ... manufacturers in China . The order ... revenue guidance of + 1 000 MSEK for 2015.  ...
(Date:3/30/2015)... Mar. 26, 2015 Research and Markets ... "Global Gesture Recognition Market in Automotive Sector 2014-2018" ... forecast the Global Gesture Recognition market in Automotive Sector ... period 2013-2018. Gesture recognition is the ability ... gestures of an individual. Gesture recognition technology can be ...
(Date:3/24/2015)... PALM BEACH GARDENS, Fla. , March 24, ... of biometric identity management solutions, today announced that ... enabling premium clothing accessory retailer Goorin Bros ... login. The Crossmatch biometrics-based solution secures access to ... customers from the increased risk of data breaches. ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2
... at high latitudes grow better than their counterparts closer ... The study, published in the February issue of The ... Bergmann,s Rule, the observation that animals tend to be ... Bergmann made his observation about latitude and size in ...
... Centers for Disease Control and Prevention, the U.S. Food and ... and Inspection Service are investigating a multistate outbreak of Salmonella ... University of Iowa confirmed on Monday, Jan. 25, that this ... sickened 187 people in 39 states (one case in Iowa) ...
... Professor of Philosophy at Stevens Institute of Technology, was recently ... 2009 in History of Science by the History of Science ... Letters at Stevens, was co-author of the paper, "After the ... wrote the paper with Angela N. H. Creager, a Professor ...
Cached Biology News:Better food makes high-latitude animals bigger 2Hygienic Lab at U. Iowa first to confirm salmonella in nationwide outbreak 2
KNP-1 (HES1) Purified Anti-Mouse, Anti-Rat, Anti-Human, Anti-Dog, Anti-Chicken clone 35, Isotype Mouse IgG 1 , 150 µg Consult technical datasheet for details....
... E978 GenBank Accession ... Immunogen : NY-ESO-1 full-length ... ascites with 0.05% sodium ... evaluated by immunoblot on ...
NATIVE RAT OSTEOCALCIN...
Form: Ready to use Applications: Immunohistology-frozen, Immunohistology-paraffin, Western Blot, ELISA...
Biology Products: